Eltanexor vs Selinexor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: XPO1 (exportin-1) · full Multiple Myeloma pipeline
Eltanexor
Developed by Karyopharm Therapeutics
NCT02649790 · Phase 1/2 · completed
The study was nonrandomized, open-label, sequential, and had no comparator arm; its estimated enrollment was 277 participants across multiple cancer indications. Although it included clinical endpoints such as response, progression-free survival, and overall survival, no primary endpoint results are posted.
No aligned efficacy figure on record for this race.
Selinexor
Marketed by Karyopharm Therapeutics and partners
NCT03110562 · Phase 3 · completed
The trial randomized 402 participants to selinexor-based therapy or an active bortezomib/dexamethasone control, but treatment was open-label rather than blinded. Its hard clinical primary endpoint, independent-reviewer progression-free survival, was met, with a median of 13.93 versus 9.46 months and p=0.0075; participants in the control arm could later cross over to selinexor treatment after progression.
Next expected readout: December 2026 · NCT06822972 (registry estimate)
Reported efficacy
SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78) (met)
Result source: NCT03110562
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Eltanexor | Selinexor |
|---|---|---|
| PFS, median | —Not reported | 13.9 vs 9.5vs Bortezomib + DexamethasoneNCT031105626 other results
|
| OS, median | —Not reported | 36.7 vs 32.8vs Bortezomib + DexamethasoneNCT031105622 other results
|
| ORR | —Not reported | 76.4% vs 62.3%vs Bortezomib + DexamethasoneNCT031105622 other results
|
| VGPR or better | —Not reported | 44.6% vs 32.4%vs Bortezomib + DexamethasoneNCT03110562 |
| MRD negativity | —Not reported | 33.3%bNCT027806093 other results
|
PFS, median
- Eltanexor
- —Not reported
- Selinexor
- 13.9 vs 9.5vs Bortezomib + DexamethasoneNCT03110562
6 other results
- 6.6 vs 8.8 NCT03110562
- 3.9 vs 8.8 NCT03110562
- 3.9 NCT03110562
- 4.7 NCT02336815
- 3.7 NCT02336815
- 3.7 NCT03944057
OS, median
- Eltanexor
- —Not reported
- Selinexor
- 36.7 vs 32.8vs Bortezomib + DexamethasoneNCT03110562
2 other results
- 7.3 NCT02336815
- 8.4 NCT02336815
ORR
- Eltanexor
- —Not reported
- Selinexor
- 76.4% vs 62.3%vs Bortezomib + DexamethasoneNCT03110562
2 other results
- 19% NCT03110562
- 26.2% NCT02336815
VGPR or better
- Eltanexor
- —Not reported
- Selinexor
- 44.6% vs 32.4%vs Bortezomib + DexamethasoneNCT03110562
MRD negativity
- Eltanexor
- —Not reported
- Selinexor
- 33.3%bNCT02780609
3 other results
- 16.7% NCT02780609
- 33.3% NCT02780609
- 100% NCT02780609
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Eltanexor: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Eltanexor: 0 of 4 rows · Selinexor: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Selinexor |
|---|---|
| Dropout rate | n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib + a NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 show 9 more results—SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 —SdX Arm: Selinexor + Dexamethasone NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 n/a: no completion milestonePart 1 NCT02336815 · Phase 2 n/a: no completion milestonePart 2 NCT02336815 · Phase 2 0% NCT03944057 · Phase 2 · registry result, not featured evidence · combination 0%Phase 1 Level 1: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1 Level 2: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1 Level 3: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 2: Selinexor Plus HDM HCT NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 0.5%SVd Arm: Selinexor + Bortezomib + a NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 show 9 more results—SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 —SdX Arm: Selinexor + Dexamethasone NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 22.8%Part 1 NCT02336815 · Phase 2 31.7%Part 2 NCT02336815 · Phase 2 — NCT03944057 · Phase 2 · registry result, not featured evidence · combination —Phase 1 Level 1: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1 Level 2: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1 Level 3: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Selinexor Plus HDM HCT NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 55.9%SVd Arm: Selinexor + Bortezomib + a NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 show 9 more results42.4%SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 50%SdX Arm: Selinexor + Dexamethasone NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 57%Part 1 NCT02336815 · Phase 2 63.4%Part 2 NCT02336815 · Phase 2 54.9% NCT03944057 · Phase 2 · registry result, not featured evidence · combination 100%Phase 1 Level 1: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Phase 1 Level 2: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination 50%Phase 1 Level 3: Selinexor Plus HD NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination 50%Phase 2: Selinexor Plus HDM HCT NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a thrombocytopenia 61.5% nausea 50.3% fatigue 42.1% NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 show 9 more resultsthrombocytopenia 50% anaemia 45.5% nausea 39.4% NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 weight decreased 42.9% cough 28.6% decreased appetite 28.6% NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3 decreased platelet count 87.8% anemia 86.6% decreased white-cell count 82.9% NCT03944057 · Phase 2 · registry result, not featured evidence · combination febrile neutropenia 33.3% nausea 33.3% thromboembolic event 33.3% NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination febrile neutropenia 33.3% hyperglycemia 33.3% urinary tract infection 33.3% NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination diarrhea 33.3% febrile neutropenia 33.3% white blood cell decreased 33.3% NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination platelet count decreased 100% white blood cell decreased 100% neutrophil count decreased 80% NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Selinexor
show 2 more results
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eltanexor's landscape · Selinexor's landscape